1. Home
  2. INBS vs GRDX Comparison

INBS vs GRDX Comparison

Compare INBS & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$2.91

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.05

Market Cap

7.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INBS
GRDX
Founded
2016
N/A
Country
United States
United Kingdom
Employees
N/A
2
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
INBS
GRDX
Price
$2.91
$2.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.6K
81.8K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
68.65
N/A
EPS
N/A
N/A
Revenue
$1,980,484.00
N/A
Revenue This Year
$778.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$1.87
52 Week High
$24.90
$5.30

Technical Indicators

Market Signals
Indicator
INBS
GRDX
Relative Strength Index (RSI) 25.10 39.99
Support Level $1.49 N/A
Resistance Level $7.25 $2.56
Average True Range (ATR) 0.30 0.20
MACD 0.05 0.02
Stochastic Oscillator 0.74 20.29

Price Performance

Historical Comparison
INBS
GRDX

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: